Company Filing History:
Years Active: 2016
Title: Eugénia Sofia Da Costa Nogueira: Innovator in Liposomal Technology
Introduction
Eugénia Sofia Da Costa Nogueira is a notable inventor based in Pousa, Portugal. She has made significant contributions to the field of liposomal technology, particularly in the development of methods that enhance drug delivery systems. Her innovative approach focuses on the use of conjugated peptide sequences to improve the efficacy of liposomal membranes.
Latest Patents
Eugénia holds a patent for "Liposomes and its production method." This invention utilizes conjugated peptide sequences for inclusion in liposomal membranes. The method allows for the combination of these peptides with folic acid or an antibody of the folic acid receptor, which is coupled to an N-terminal peptide. The incorporation of these peptides enables targeted delivery and release of therapeutic and imaging agents to cells that express the folic acid receptor. This advancement combines the transport capabilities of liposomes with the specific expression of folic acid receptors on cell membranes, facilitating the transmembrane transport of both hydrophobic and hydrophilic agents. The therapeutic agents can include pharmacological compounds or siRNAs specific to defined target genes.
Career Highlights
Eugénia is affiliated with the University of Minho, where she continues her research and development in innovative drug delivery systems. Her work has garnered attention for its potential applications in medical therapies and diagnostics.
Collaborations
Eugénia has collaborated with notable colleagues, including Artur Manuel Cavaco Paulo and Ana Arminda Lopes Preto De Almeida. These collaborations have contributed to the advancement of her research and the successful development of her patented technologies.
Conclusion
Eugénia Sofia Da Costa Nogueira is a pioneering inventor whose work in liposomal technology has the potential to revolutionize drug delivery systems. Her innovative methods and collaborations highlight her commitment to advancing medical science.